NASDAQ$BCPC
Balchem Corporation · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Balchem reported record third-quarter sales and earnings, driven by growth across all three segments amidst macroeconomic challenges.
Balchem Corporation reported record third-quarter results, with net sales reaching $197.9 million and net earnings of $25.0 million. The company's performance reflects the strength of its global market positions and the resilience of its business model in the face of global supply chain disruptions and input cost inflation.
- Net sales increased by 13.0% to $197.9 million, with record sales in Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments.
- GAAP net earnings rose by 16.0% to $25.0 million, resulting in GAAP earnings per share of $0.77.
- Adjusted EBITDA increased by 8.8% to $48.3 million.
- Cash flows from operations were $39.6 million, with free cash flow of $31.1 million.
Headline financials
Revenue & EPS history
Balchem · Revenue · Quarterly
$198M
Revenue by segment
Balchem · $195M total across 3 segments · Q3 2021
- Human Nutrition & Health$111M+7.3%57.0%
- Animal Nutrition & Health$56.2M+21.2%28.8%
- Specialty Products$27.6M+20.0%14.2%
Forward guidance
Balchem anticipates macroeconomic challenges, including global supply chain disruptions and input cost inflation, to persist and potentially intensify into the fourth quarter and the following year. Mitigating these impacts will be a key focus for the Balchem team.
Headwinds
- Global supply chain disruptions are expected to continue and accelerate.
- Input cost inflation is expected to continue and accelerate.
- Mitigating these impacts will remain a key focus for the Balchem team.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.0%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+0.9%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+25.0%
Q1 2014
Best reaction
-16.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.8% | -7.0% | -9.7% | |
| Q4 2025 | -2.3% | +2.6% | -7.4% | |
| Q3 2025 | +4.1% | +3.9% | +1.3% | |
| Q1 2025 | -2.6% | -1.5% | +4.8% | |
| Q4 2024 | +1.5% | +7.0% | -0.1% | |
| Q3 2024 | +2.8% | +1.6% | +9.8% | |
| Q2 2024 | +3.9% | +1.5% | -1.2% | |
| Q1 2024 | -1.8% | -3.0% | -8.8% | |
| Q4 2023 | +7.4% | +5.0% | +6.8% | |
| Q3 2023 | -5.0% | -4.1% | +1.1% | |
| Q2 2023 | +4.8% | +5.0% | +7.1% | |
| Q1 2023 | +1.7% | +0.5% | +5.2% | |
| Q4 2022 | -2.0% | -0.2% | -7.7% | |
| Q3 2022 | -0.6% | -0.5% | +5.4% | |
| Q2 2022 | -5.2% | -6.6% | +2.3% | |
| Q1 2022 | +1.6% | -0.9% | -10.5% | |
| Q4 2021 | +1.0% | -0.7% | +1.2% | |
| Q3 2021 | -0.8% | +2.3% | +7.9% | |
| Q2 2021 | -0.8% | -2.5% | +2.7% | |
| Q1 2021 | -0.2% | -0.1% | +0.5% | |
| Q4 2020 | +5.4% | +6.4% | +10.7% | |
| Q3 2020 | -1.7% | -0.5% | +3.3% | |
| Q2 2020 | +4.6% | +4.7% | +0.3% | |
| Q1 2020 | -5.4% | -3.9% | -9.3% | |
| Q4 2019 | -10.7% | -13.3% | -15.9% | |
| Q3 2019 | +2.9% | +1.2% | -0.8% | |
| Q2 2019 | -16.3% | -15.9% | -13.5% | |
| Q1 2019 | +1.1% | +4.0% | +9.4% | |
| Q4 2018 | +8.0% | +12.4% | +10.7% | |
| Q3 2018 | -4.9% | -4.9% | -13.7% | |
| Q2 2018 | +1.1% | +1.3% | +10.1% | |
| Q1 2018 | -1.3% | +2.2% | +7.9% | |
| Q4 2017 | +2.3% | +5.9% | +8.6% | |
| Q3 2017 | +1.0% | -0.7% | +1.3% | |
| Q2 2017 | -2.6% | -3.9% | -1.8% | |
| Q1 2017 | -3.3% | -5.3% | -1.8% | |
| Q4 2016 | +5.2% | +2.2% | -2.5% | |
| Q3 2016 | -4.5% | +0.8% | +12.3% | |
| Q2 2016 | +1.3% | +2.0% | +8.7% | |
| Q1 2016 | +0.3% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -2.0% | — | — | |
| Q2 2015 | +5.2% | — | — | |
| Q1 2015 | -0.5% | — | — | |
| Q4 2014 | -3.4% | — | — | |
| Q3 2014 | +6.7% | — | — | |
| Q2 2014 | +2.5% | — | — | |
| Q1 2014 | +25.0% | — | — | |
| Q4 2013 | +0.4% | — | — | |
| Q3 2013 | -4.9% | — | — | |
| Q2 2013 | +1.3% | — | — | |
| Q1 2013 | -2.3% | — | — | |
| Q4 2012 | +0.8% | — | — | |
| Q3 2012 | -10.5% | — | — | |
| Q2 2012 | +5.9% | — | — | |
| Q1 2011 | +2.1% | — | — | |
| Q4 2011 | +2.1% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q1 2010 | -4.1% | — | — | |
| Q4 2009 | -4.1% | — | — | |
| Q3 2010 | -3.2% | — | — | |
| Q3 2011 | -3.2% | — | — | |
| Q2 2011 | +1.0% | — | — | |
| Q4 2010 | +1.0% | — | — | |
| Q2 2010 | +1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro